| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
|
| Targets |
JNK;MMP13
|
|---|---|
| ln Vitro |
The HIF-1α pathway in NSCLC cells is inhibited by chloramphenicol (1-100 μg/mL, 18-24 h) in a concentration-dependent manner.NSCLC cells are exposed to 100 μg/mL of chloramphenicol for 0–24 hours, which causes autophagy induction and significantly raises the levels of autophagic biomarkers (beclin-1, Atg12–Atg5 conjugates, and LC3–II)[1].
In activated T cells, chloramphenicol inhibits apoptosis and causes aberrant differentiation[2]. Chloramphenicol can cause reduced ATP biosynthesis and mitochondrial stress by blocking the synthesis of proteins in both bacteria and mitochondria[3]. Chloramphenicol (1-100 μg/mL) has the ability to upregulate MMP-13 protein and stimulate the expression of matrix metalloproteinase (MMP)-13[3]. Chloramphenicol (1-100 μg/mL) has the ability to stimulate PI-3K/Akt signaling, c-Jun protein phosphorylation, and c-Jun N-terminal kinases (JNK)[3]. By inhibiting peptidyl transferase activity, chloramphenicol mainly affects the 50S subunit of bacterial 70S rihosomes, which prevents the formation of peptide bonds[5]. |
| ln Vivo |
Day 1 post-dosing sees a decrease in marrow erythroid cells and erythrocyte precursors, and by day 14, after 14 days of treatment, erythrocytes and erythrocyte precursors have returned to normal[4].
|
| Animal Protocol |
Animal Model: Female B6C3F1 mice (12-14 weeks old)
Dosage: 0, 2500 and 3500 mg/kg Administration: Gavage, daily, for 5 days Result: On the first day after dosage, erythropoiesis was clearly stopped. At the 2500 mg/kg dose level on day 7 and between 7 and 14 days at the 3500 mg/kg dose level, respectively, a recovery was observed after the dosage. At every dosage level, the erythroid series showed the greatest myelotoxicity. Day 1 post-dosage: decreased femoral marrow BFU-E and CFU-E. Within 14 days of the dosage, every blood and marrow parameter in the current study was back to normal. |
| References |
|
| Molecular Formula |
C11H12CL2N2O5
|
|---|---|
| Molecular Weight |
323.13
|
| Exact Mass |
322.0123
|
| Elemental Analysis |
C, 40.89; H, 3.74; Cl, 21.94; N, 8.67; O, 24.76
|
| CAS # |
56-75-7
|
| Related CAS # |
Chloramphenicol-d5;202480-68-0;Chloramphenicol palmitate;530-43-8;Levomecol;118573-58-3;DL-threo-Chloramphenicol-d5;1420043-66-8;Threo-Chloramphenicol-d6;Chloramphenicol-d4
|
| Appearance |
White to off-white crystalline powder.
|
| SMILES |
C1=CC(=CC=C1C(C(CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-]
|
| InChi Key |
WIIZWVCIJKGZOK-RKDXNWHRSA-N
|
| InChi Code |
InChI=1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1
|
| Chemical Name |
2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide
|
| Synonyms |
Chloramphenicol; Chlornitromycin; Chloromycetin; Levomycetin; Chlorocid; Globenicol; Detreomycin; Kloramfenikol; Levomycetin; Ophthochlor; Syntomycin;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :65~150 mg/mL (201.15~464.21 mM )
Ethanol : ~100 mg/mL (~309.47 mM ) H2O : ~3.06 mg/mL (~9.47 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.74 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (7.74 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 2.5 mg/mL (7.74 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: ≥ 2.5 mg/mL (7.74 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 7: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (7.74 mM) Solubility in Formulation 8: 2.5 mg/mL (7.74 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0947 mL | 15.4736 mL | 30.9473 mL | |
| 5 mM | 0.6189 mL | 3.0947 mL | 6.1895 mL | |
| 10 mM | 0.3095 mL | 1.5474 mL | 3.0947 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
